C07K 16/2836
Against cd106
Official title: {against CD106}
C07K16/2836 (Against cd106) appears on 64 US grants and 110 published applications in this corpus.
Search patents in C07K- Granted patents
- 64
- Published applications
- 110
- Assignees
- 59
- Inventors
- 155
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 3 |
| 2003 | 0 | 5 |
| 2004 | 1 | 12 |
| 2005 | 0 | 7 |
| 2006 | 1 | 3 |
| 2007 | 2 | 4 |
| 2008 | 4 | 1 |
| 2009 | 9 | 2 |
| 2010 | 5 | 5 |
| 2011 | 3 | 1 |
| 2012 | 0 | 10 |
| 2013 | 6 | 3 |
| 2014 | 4 | 10 |
| 2015 | 2 | 7 |
| 2016 | 2 | 4 |
| 2017 | 3 | 4 |
| 2018 | 3 | 1 |
| 2019 | 0 | 4 |
| 2020 | 1 | 4 |
| 2021 | 2 | 7 |
| 2022 | 0 | 4 |
| 2023 | 3 | 4 |
| 2024 | 3 | 3 |
| 2025 | 2 | 2 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for generating avid-binding multispecific antibodies3 Mar 2026US 12,565,536 B2Hoffmann-La Roche Inc.
- Compositions and methods of treating cancer with chimeric antigen receptors1 Apr 2025US 12,264,190 B2AstraZeneca AB
- Activatable anti-VEGF scFv28 Jan 2025US 12,209,120 B2CytomX Therapeutics, Inc.
- Methods of treatment by targeting VCAM1 and MAEA24 Dec 2024US 12,173,073 B2Albert Einstein College of Medicine
- Methods for targeted delivery of agents to degraded elastic fibers7 May 2024US 11,975,109 B2Clemson University Research Foundation
- Composition for preventing or treating myocarditis, comprising vla-4 inhibitor26 Jun 2025US 2025/0206825 A1Osaka University
- Anti-cMET Antibodies and Methods of Use15 May 2025US 2025/0154265 A1BeiGene, Ltd.
- Engineering method for mesenchymal stem cells based on polyvalent antibody and application thereof31 Oct 2024US 2024/0360221 A1South China University of Technology
- Targeted Therapeutic Lipid Nanoparticles and Methods of Use13 Jun 2024US 2024/0189445 A1The Trustees of the University of Pennsylvania
- Compositions and methods of treating cancer with chimeric antigen receptors16 May 2024US 2024/0158469 A1AstraZeneca AB
Most cited
By later US patents
- Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids112US 6,312,694 B1Board of Regents, The University of Texas System · 2001
- Activatable binding polypeptides and methods of identification and use thereof79US 8,518,404 B2CytomX Therapeutics, Inc. · 2013
- Activatable binding polypeptides and methods of identification and use thereof68US 8,541,203 B2CytomX Therapeutics, Inc. · 2013
- Activatable binding polypeptides and methods of identification and use thereof67US 8,529,898 B2CytomX Therapeutics, Inc. · 2013
- Activatable binding polypeptides and methods of identification and use thereof64US 9,169,321 B2CytomX Therapeutics, Inc. · 2015